✉ Email this page to a colleague
« Back to Dashboard
threo-3-methyl-L-aspartic acid is an investigational drug.
There have been 7 clinical trials for threo-3-methyl-L-aspartic acid. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2008.
The most common disease conditions in clinical trials are Hypotension, Orthostatic, Hypotension, and Autonomic Nervous System Diseases. The leading clinical trial sponsors are Chelsea Therapeutics, Chiltern International Inc., and University Hospital, Toulouse.
Recent Clinical Trials for threo-3-methyl-L-aspartic acid
|Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA||University Hospital, Toulouse||Phase 2/Phase 3|
|Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome||Chelsea Therapeutics||Phase 2|
|A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease||Chelsea Therapeutics||Phase 3|